North America Archives - Page 14 of 39 - Journal for Clinical Studies

Current Edition

Europe

Aimmune’s peanut drug moves closer to European market

An experimental peanut allergy drug from Aimmune Therapeutics has met the primary endpoint of a Phase 3 European study, according to topline data released by the com...

28 March 2019 Europe | news | North America | Regional News

Continue Reading →

news

Conatus drug misses goal, hitting NASH stocks

Conatus Pharmaceuticals on Thursday disclosed its lead liver disease drug emricasan missed its primary goal in a Phase 2b study of patients with non-alcoholic steato...

28 March 2019 news | North America | Regional News

Continue Reading →

news

PCI Announces Expansion of High Potent Tableting and Powder Modification Capacity

Investment in new technologies at PCI’s global manufacturing Center of Excellence in Tredegar, Wales, to double highly potent tableting capacity and boost powder han...

25 March 2019 news | North America | Regional News

Continue Reading →

news

PCI Pharma Services Appoints New Chief Financial Officer, SVP, Serge Dupuis

Philadelphia, PA – 22 March, 2019. Leading global biopharmaceutical outsourcing services provider PCI Pharma Services (PCI) is pleased to welcome Serge Dupuis as Sen...

25 March 2019 news | North America | Regional News

Continue Reading →

news

Researchers report promising results of potential reversal agent

In patients with acute coronary syndromes, coronary artery stenting, or a history of prior heart attacks, antiplatelet therapy can be lifesaving. Ticagrelor, in comb...

21 March 2019 news | North America | Regional News

Continue Reading →

news

Apple heart study: Early proof of concept, or a bit of a gimmick?

Preliminary results in a study of Apple Watch's ability to track heart data found 0.5%, or 2,161 people, received notifications of a potential irregular heartbeat an...

21 March 2019 news | North America | Regional News

Continue Reading →

news

Lilly’s Cyramza comes up positive in first-line lung cancer trial

Eli Lilly's anti-angiogenic therapy Cyramza met the primary endpoint of a late-stage study, improving progression-free survival in previously untreated patients with...

21 March 2019 news | North America | Regional News

Continue Reading →

news

Pfizer, Merck KGaA scrap yet another Bavencio ovarian cancer trial

Pfizer and Merck KGaA are dismantling their second phase 3 ovarian cancer study for Bavencio since December. Pfizer and Merck KGaA have had a rough go at broaden...

21 March 2019 news | North America

Continue Reading →

news

Tecentriq assumes pole position with FDA approval but Keytruda looms in triple negative breast cancer, says GlobalData

On March 8, the FDA granted the accelerated approval of Roche’s programmed cell death protein 1 (PD-1) inhibitor Tecentriq in combination with Abraxane (protein-boun...

21 March 2019 news | North America | Regional News

Continue Reading →

news

Ardelyx’s Tenapanor may be answer to growing demand for novel CKD-MBD treatments, says GlobalData

Even though the chronic kidney disease–mineral bone disorder (CKD-MBD) market is set to face several barriers to growth over the next decade, the anticipated launch ...

21 March 2019 news | North America | Regional News

Continue Reading →